<DOC>
	<DOCNO>NCT01236287</DOCNO>
	<brief_summary>Voclosporin investigational medication previously study prevent acute rejection patient receive kidney transplant . This study compassionate release program subject previously participate study entitle A Phase 2B , Randomized , Multicenter , Open-Label , Concentration Controlled , Safety Study ISA247 Tacrolimus ( Prograf® ) denovo Renal Transplant Patients ( ISA05-01 ) '' may eligible continue receive voclosporin despite Phase 2B study terminate sponsor . Under compassionate release program , subject previously take voclosporin may continue receive study medication drug FDA-approved commercially available United States .</brief_summary>
	<brief_title>Special Access Use Voclosporin Kidney Transplantation</brief_title>
	<detailed_description>Voclosporin investigational medication previously study prevent acute rejection patient receive kidney transplant . This study compassionate release program subject previously participate study entitle A Phase 2B , Randomized , Multicenter , Open-Label , Concentration Controlled , Safety Study ISA247 Tacrolimus ( Prograf® ) denovo Renal Transplant Patients ( ISA05-01 ) '' may eligible continue receive voclosporin despite Phase 2B study terminate sponsor . Under compassionate release program , subject previously take voclosporin may continue receive study medication drug FDA-approved commercially available United States . Subjects receive voclosporin follow outpatient setting . After initial visit , patient return follow-up least every 3 month ( month 24 ) every 6 month ( begin month 24 ) . Safety efficacy measurement take appropriate time point outline table . Trough voclosporin measurement collect least every 3 month ( month 24 ) every 6 month ( begin month 24 ) frequently clinic visit appropriate ( indicated clinical event ( rejection , infection , adverse event ) concomitant administration interact medication . Patient graft survival data collect annual basis safety reporting .</detailed_description>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Subjects currently enrol `` A Phase 2B , Randomized , Multicenter , OpenLabel , Concentration Controlled , Safety Study ISA247 Tacrolimus ( Prograf® ) denovo Renal Transplant Patients ( ISA0501 ) '' compel reason remain voclosporin Subjects must provide Informed Consent participate study Females childbearing potential must negative pregnancy test prior enrollment Subjects already switch voclosporin ( ISA247 ) another immunosuppressive agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>